STAT3 as a biomarker of progression in atypical nevi of patients with melanoma: dose-response effects of systemic IFNalpha therapy (Q80786921)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18305569%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

title

STAT3 as a biomarker of progression in atypical nevi of patients with melanoma: dose-response effects of systemic IFNalpha therapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18305569%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

1 reference

Wenjun Wang

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18305569%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

Howard D Edington

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18305569%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

Uma N M Rao

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18305569%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

Drazen M Jukic

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18305569%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

Hong Wang

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18305569%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

Janice M Shipe-Spotloe

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18305569%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

John M Kirkwood

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18305569%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

language of work or name

English

0 references

publication date

28 February 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18305569%20AND%20SRC:MED&resulttype=core&format=json

Journal of Investigative Dermatology

3 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18305569%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

volume

128

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18305569%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18305569%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

page(s)

1997-2002

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18305569%20AND%20SRC:MED&resulttype=core&format=json

Grading of atypia in nevi: correlation with melanoma risk

3 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.26

7 January 2021

Down-regulation of the interferon signaling pathway in T lymphocytes from patients with metastatic melanoma.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.26

7 January 2021

Precursors to melanoma and their mimics: nevi of special sites

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.26

7 January 2021

Gene expression changes and signaling events associated with the direct antimelanoma effect of IFN-gamma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.26

7 January 2021

Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.26

7 January 2021

Regulation of metastases by signal transducer and activator of transcription 3 signaling pathway: clinical implications

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.26

7 January 2021

Melanocytic dysplastic naevi occupy the middle ground between benign melanocytic naevi and cutaneous malignant melanomas: emerging clues

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.26

7 January 2021

STAT3 and MITF cooperatively induce cellular transformation through upregulation of c-fos expression

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.26

7 January 2021

High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.26

7 January 2021

Interferon alfa-2a for melanoma metastases.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.26

7 January 2021

High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.26

7 January 2021

A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.26

7 January 2021

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.26

7 January 2021

The antitumor effects of IFN-alpha are abrogated in a STAT1-deficient mouse

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.26

7 January 2021

The prevalence of interferon-alpha transcription defects in malignant melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.26

7 January 2021

JAK-STAT signaling: from interferons to cytokines

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.26

7 January 2021

Variability in nomenclature used for nevi with architectural disorder and cytologic atypia (microscopically dysplastic nevi) by dermatologists and dermatopathologists

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.26

7 January 2021

The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.26

7 January 2021

Modulation of signal transducers and activators of transcription 1 and 3 signaling in melanoma by high-dose IFNalpha2b.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.26

7 January 2021

Regulation of transforming growth factor-beta 1-induced apoptosis and epithelial-to-mesenchymal transition by protein kinase A and signal transducers and activators of transcription 3.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.26

7 January 2021